Wyeth Reports Earnings Results for the 2008 Third Quarter and First N...(eprior year: ...)

(UNAUDITED)

Three Months Ended Nine Months Ended

9/30/2008 9/30/2008

Increase/ Increase/

Principal Products $in millions (Decrease) $in millions (Decrease)

Effexor $982 3% $3,026 7%

Prevnar 717 13% 2,113 12%

Enbrel

Outside U.S. and Canada 697 32% 1,995 35%

Alliance Revenue -

U.S. and Canada 294 23% 904 23%

Nutritionals 408 18% 1,249 19%

Zosyn/Tazocin 305 7% 966 14%

Premarin family 262 (8)% 809 2%

Protonix Family(1) 234 (45)% 621 (57)%

Centrum 186 7% 558 11%

Advil 165 (7)% 502 1%

(1) Protonix family net revenue for the 2008 third quarter and first nine months reflects revenue from both the branded product, $92 and $279, respectively, and Wyeth's own generic version, $142 and $342, respectively.

2008 Third Quarter Results

Overall net revenue increased 4% for the 2008 third quarter, primarily driven by Wyeth's key pharmaceutical franchises, such as ENBREL(R), PREVNAR(R) and Nutritional products, as well as the favorable impact of foreign exchange. Partially offsetting the increases were lower sales of the PROTONIX(R) family.

Selling, general and administrative expenses, excluding certain significant items, decreased 6% for the 2008 third quarter (7% excluding the impact of foreign exchange) versus the 2007 third quarter, primarily due to the realizati
'/>"/>